EFS and OS by era
| . | Patients age 65 years or younger . | Patients older than age 65 years . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Era 1 . | Era 2 . | Log-rank P . | sMIPI- adjusted HR . | Cox regression P . | Era 1 . | Era 2 . | Log-rank P . | sMIPI- adjusted HR . | Cox regression P . | |
| All patients | ||||||||||
| EFS, y | 2.9 (2.1-3.6) | 4.3 (2.8-NA) | .010 | 0.60 (0.41-0.87) | .007 | 2.0 (1.0-3.3) | 3.0 (1.8-5.1) | .051 | 0.73 (0.51-1.04) | .086 |
| 5-y EFS, % | 34.3 (25.9-45.5) | 50.0 (40.2-62.2) | 25.4 (17.5-36.9) | 37.5 (28.1-50.1) | ||||||
| 5-y OS, % | 68.8 (60.0-78.9) | 81.6 (73.8-90.2) | .017 | 0.55 (0.33-0.90) | .018 | 48.2 (38.5-60.4) | 53.2 (43.1-65.6) | .136 | 0.79 (0.53-1.19) | .259 |
| Patients treated with standard immunochemotherapy* | ||||||||||
| Median EFS, y | 3.1 (2.3-4.5) | 6.4 (2.8-NA) | .012 | 0.56 (0.37-0.85) | .007 | 1.3 (0.8-3.3) | 4.2 (3.0-NA) | .008 | 0.42 (0.24-0.73) | .002 |
| 5-y EFS, % | 36.8 (27.3-49.4) | 53.8 (43.2-67.0) | 25.0 (13.7-45.6) | 44.6 (32.6-61.1) | ||||||
| 5-y OS, % | 69.7 (60.1-80.9) | 83.7 (75.6-92.6) | .013 | 0.48 (0.27-0.84) | .010 | 46.9 (32.4-67.8) | 53.0 (40.7-69.0 | .076 | 0.54 (0.30-0.95) | .033 |
| Patients treated with nonstandard systemic therapy or nonsystemic therapy | ||||||||||
| Median EFS, y | 1.9 (1.1-8.8) | 3.3 (0.9-NA) | .424 | 0.85 (0.35-2.08) | .721 | 2.3 (1.8-3.8) | 1.7 (0.9-4.2) | .233 | 1.57 (0.93-2.66) | .091 |
| 5-y EFS, % | 23.5 (10.0-55.4) | 28.6 (11.3-72.2) | 24.4 (14.8-40.4) | 23.1 (11.4-46.6) | ||||||
| 5-y OS, % | 64.7 (45.5-91.9) | 68.6 (46.6-100.0) | .767 | 1.65 (0.46-5.94) | .447 | 49.1 (36.7-65.6) | 50.0 (34.0-73.4) | .980 | 1.24 (0.67-2.29) | .501 |
| . | Patients age 65 years or younger . | Patients older than age 65 years . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Era 1 . | Era 2 . | Log-rank P . | sMIPI- adjusted HR . | Cox regression P . | Era 1 . | Era 2 . | Log-rank P . | sMIPI- adjusted HR . | Cox regression P . | |
| All patients | ||||||||||
| EFS, y | 2.9 (2.1-3.6) | 4.3 (2.8-NA) | .010 | 0.60 (0.41-0.87) | .007 | 2.0 (1.0-3.3) | 3.0 (1.8-5.1) | .051 | 0.73 (0.51-1.04) | .086 |
| 5-y EFS, % | 34.3 (25.9-45.5) | 50.0 (40.2-62.2) | 25.4 (17.5-36.9) | 37.5 (28.1-50.1) | ||||||
| 5-y OS, % | 68.8 (60.0-78.9) | 81.6 (73.8-90.2) | .017 | 0.55 (0.33-0.90) | .018 | 48.2 (38.5-60.4) | 53.2 (43.1-65.6) | .136 | 0.79 (0.53-1.19) | .259 |
| Patients treated with standard immunochemotherapy* | ||||||||||
| Median EFS, y | 3.1 (2.3-4.5) | 6.4 (2.8-NA) | .012 | 0.56 (0.37-0.85) | .007 | 1.3 (0.8-3.3) | 4.2 (3.0-NA) | .008 | 0.42 (0.24-0.73) | .002 |
| 5-y EFS, % | 36.8 (27.3-49.4) | 53.8 (43.2-67.0) | 25.0 (13.7-45.6) | 44.6 (32.6-61.1) | ||||||
| 5-y OS, % | 69.7 (60.1-80.9) | 83.7 (75.6-92.6) | .013 | 0.48 (0.27-0.84) | .010 | 46.9 (32.4-67.8) | 53.0 (40.7-69.0 | .076 | 0.54 (0.30-0.95) | .033 |
| Patients treated with nonstandard systemic therapy or nonsystemic therapy | ||||||||||
| Median EFS, y | 1.9 (1.1-8.8) | 3.3 (0.9-NA) | .424 | 0.85 (0.35-2.08) | .721 | 2.3 (1.8-3.8) | 1.7 (0.9-4.2) | .233 | 1.57 (0.93-2.66) | .091 |
| 5-y EFS, % | 23.5 (10.0-55.4) | 28.6 (11.3-72.2) | 24.4 (14.8-40.4) | 23.1 (11.4-46.6) | ||||||
| 5-y OS, % | 64.7 (45.5-91.9) | 68.6 (46.6-100.0) | .767 | 1.65 (0.46-5.94) | .447 | 49.1 (36.7-65.6) | 50.0 (34.0-73.4) | .980 | 1.24 (0.67-2.29) | .501 |
All data are median (95% CI).
NA, not achieved.
Regimens included R-Hyper-CVAD/R-MA, Nordic regimen, R-CHOP/R-DHAP, R-CHOP or R-CHOP-like, and R-bendamustine. Data for older patients were based on R-CHOP or R-CHOP-like and R-bendamustine outcomes only.